Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Published on 4 April 2025

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants.

Explore posts connected to this topic

Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that...

Press Releases

September 15, 2026

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California

Press Releases

June 26, 2026

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

Press Releases

May 8, 2026

San Diego, CA, and Bergisch Gladbach, Germany – September 15,

Press Releases

September 15, 2026